BIOMAT Database Logo BIOMAT Database Logo

Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. 2019

Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Minhang Hospital & Department of Clinical Pharmacy at School of Pharmacy, Fudan University, 201203, PR China. Electronic address: 18211030045@fudan.edu.cn.

Atorvastatin and its lactone form metabolite are reported to be associated with statin-induced myopathy (SIM) such as myalgia and life-threatening rhabdomyolysis. Though the statin-induced rhabdomyolysis is not common during statin therapy, its incidence will significantly increase due to pharmacokinetic drug-drug interactions (DDIs) with inhibitor drugs which inhibit atorvastatin's and its lactone's metabolism and hepatic uptake. Thus, the quantitative analysis of DDIs of atorvastatin and its lactone with cytochrome P450 3A4 (CYP3A4) and organic anion-transporting polypeptide (OATP) inhibitors is of great importance. This study aimed to predict pharmacokinetic DDIs possibly causing atorvastatin-induced rhabdomyolysis using Physiologically Based Pharmacokinetic (PBPK) Modelling. Firstly, we refined the PBPK models of atorvastatin and atorvastatin lactone for predicting the DDIs with CYP3A4 and OATP inhibitors. Thereafter, we predicted the exposure changes of atorvastatin and atorvastatin lactone originating from the case reports of atorvastatin-induced rhabdomyolysis using the refined models. The simulation results show that pharmacokinetic DDIs of atorvastatin and its lactone with fluconazole, palbociclib diltiazem and cyclosporine are significant. Consequently, clinicians should be aware of necessary dose adjustment of atorvastatin being used with these four inhibitor drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069059 Atorvastatin A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors. (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid,Atorvastatin Calcium,Atorvastatin Calcium Anhydrous,Atorvastatin Calcium Hydrate,Atorvastatin Calcium Trihydrate,Atorvastatin, Calcium Salt,CI 981,CI-981,Lipitor,Liptonorm,CI981
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
February 2020, Biopharmaceutics & drug disposition,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Physiologically based modelling and prediction of drug interactions.
March 2010, Basic & clinical pharmacology & toxicology,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.
March 2016, Clinical pharmacokinetics,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
March 2015, Drug metabolism and disposition: the biological fate of chemicals,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
August 2022, Clinical pharmacokinetics,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
July 2013, Clinical pharmacokinetics,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
September 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
August 2017, European journal of drug metabolism and pharmacokinetics,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
December 2017, Archives of pharmacal research,
Size Li, and Yiqun Yu, and Zhiping Jin, and Yu Dai, and Haishu Lin, and Zheng Jiao, and Guo Ma, and Weimin Cai, and Bing Han, and Xiaoqiang Xiang
Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
September 2021, CPT: pharmacometrics & systems pharmacology,
Copied contents to your clipboard!